# SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

> **NCT07307287** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- SHR-A1811
- HER2-Postive Breast Cancer
- HR+ Breast Cancer
- Early Breast Cancer
- Locally Advanced Breast Cancer

## Interventions

- **DRUG:** SHR- A1811

## Key facts

- **NCT ID:** NCT07307287
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-20
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07307287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07307287, "SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07307287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*